Deuruxolitinib
Leqselvi (deuruxolitinib) is a small molecule pharmaceutical. Deuruxolitinib was first approved as Leqselvi on 2024-07-25. The pharmaceutical is active against tyrosine-protein kinase JAK2 and tyrosine-protein kinase JAK1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Leqselvi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deuruxolitinib phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LEQSELVI | Sun Pharmaceutical Industries | N-217900 RX | 2024-07-25 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| leqselvi | New Drug Application | 2025-07-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alopecia areata | EFO_0004192 | D000506 | L63 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | — | — | — | 1 | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | — | 1 | — | 1 |
| T-cell lymphoma | D016399 | — | — | — | — | — | 1 | — | 1 |
| Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 5 | 5 | — | — | 9 |
| Alopecia | D000505 | — | L64 | — | 5 | 5 | — | — | 9 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Deuruxolitinib |
| INN | deuruxolitinib |
| Description | Deuruxolitinib (CTP-543) is a Janus kinase inhibitor selective for JAK1 and JAK2. It is in development to treat alopecia areata. If approved the drug would compete with others with a similar mechanism of action developed by Eli Lilly and Pfizer.
|
| Classification | Small molecule |
| Drug class | deuterated compounds; tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | [2H]C1([2H])C([C@@H](CC#N)n2cc(-c3ncnc4[nH]ccc34)cn2)C([2H])([2H])C([2H])([2H])C1([2H])[2H] |
Identifiers
| PDB | — |
| CAS-ID | 1513883-39-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594381 |
| ChEBI ID | — |
| PubChem CID | 72704611 |
| DrugBank | DB18847 |
| UNII ID | 0CA0VSF91Y (ChemIDplus, GSRS) |
Target
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 57 documents
View more details
Safety
Black-box Warning
Black-box warning for: Leqselvi
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use